ProAxsis success at BIO 2015
Date : August 07, 2015
ProAxsis had a very successful BIO in Philadelphia this year.
Dr Lorraine Martin, CEO and co-founder, Professor Brian Walker (CSO) had meetings with a number of research groups and pharmaceutical companies who showed interest in the company’s latest product – the proprietary first-in-class ProteaseTag™ activity dependent immunoassay.
ProAxsis was in Philadelphia as part of the Invest Northern Ireland (INI) delegation. Over the 4 days the ProAxsis team were kept busy with discussions ranging from interest in their new ProteaseTag™ product, for the specific detection of active neutrophil elastase in clinical samples through to co-development and licencing opportunities.
ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. This test measures Neutrophil Elastase, a leading indicator of infection in patients with Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) and an important drug target. The rapid and easy-to-use tests incorporate patented ProteaseTags™; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags™ provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.
Dr Martin said: “Bio2015 was a great opportunity for us to showcase our unique technology. We have made a number of significant contacts from across the globe which we hope will add to future business development. Overall the Northern Ireland biotech sector had a great representation at Bio and we look forward to contributing to the sustained growth in this area.”